3-Mar-2026
Hims & Hers back in red as FDA doubles down on GLP-1 compounders
Seeking Alpha News (Tue, 3-Mar 2:01 PM ET)
Hims’ partner Strive reportedly planning to launch copies of Novo’s Wegovy pill
Seeking Alpha News (Tue, 3-Mar 10:27 AM ET)
Can Hims & Hers Overcome the FDA’s GLP-1 Crackdown?
TipRanks (Tue, 3-Mar 9:30 AM ET)
TipRanks (Tue, 3-Mar 6:35 AM ET)
Hims & Hers Stock (HIMS) Surged 13.5% — Could More Gains Be Ahead?
TipRanks (Tue, 3-Mar 1:31 AM ET)
Business Wire (Mon, 2-Mar 12:00 PM ET)
Trending stocks this week as Wall Street ends lower on Nvidia results, hot PPI data
Seeking Alpha News (Sat, 28-Feb 12:11 PM ET)
Hims, Qualcomm, IBM, First Solar, Oracle Trending With Analysts
TipRanks (Sat, 28-Feb 4:04 AM ET)
Business Wire (Fri, 27-Feb 12:00 PM ET)
Business Wire (Wed, 25-Feb 7:18 PM ET)
Hims & Hers Health Inc operates telehealth platforms, providing access to treatments for various chronic conditions, including those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. The company connects patients to licensed healthcare professionals who can prescribe medications, with prescriptions fulfilled online through licensed pharmacies. In addition, it offers access to various non-prescription health and wellness products. Through the Hims & Hers mobile applications, the company also offers access to educational programs, wellness content, community support, and other services that promote lifelong health and wellness. Geographically, it derives maximum revenue from the USA.
Hims & Hers Health Class A trades on the NYSE stock market under the symbol HIMS.
As of March 3, 2026, HIMS stock price declined to $15.82 with 25,838,941 million shares trading.
HIMS has a beta of 2.13, meaning it tends to be more sensitive to market movements. HIMS has a correlation of 0.14 to the broad based SPY ETF.
HIMS has a market cap of $3.61 billion. This is considered a Mid Cap stock.
Last quarter Hims & Hers Health Class A reported $618 million in Revenue and $.08 earnings per share. This fell short of revenue expectation by $-207,922 and exceeded earnings estimates by $.05.
In the last 3 years, HIMS traded as high as $72.98 and as low as $5.65.
The top ETF exchange traded funds that HIMS belongs to (by Net Assets): VTI, VB, IJH, IWM, VBK.
HIMS has underperformed the market in the last year with a price return of -64.9% while the SPY ETF gained +15.7%. HIMS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -56.4% and -2.9%, respectively, while the SPY returned +0.1% and -0.2%, respectively.
HIMS support price is $15.29 and resistance is $17.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HIMS shares will trade within this expected range on the day.